ODM-109

· Orion Corporation

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ODM-109, covering 2017-11-28 to 2021-08-31. Get the full timeline:

Most recent: Clinical Trial Update: Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS [Phase 3]